chrisvoncsefalvay/vaers-outcomes huggingface dataset:
fever; Chills; chest discomfort; fatigue; lymph node swelling; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 46 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 26Jan2022 13:15 (Lot number: FJ5682) at the age of 46 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "known allergies: eggs" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose 1, Lot number: EN6203, Location of injection: Arm left, Route of Administration: Intramuscular), administration date: 21Mar2021, when the patient was 45 years old, for COVID-19 Immunization; Bnt162b2 (Dose 2, Lot number: ER8730, Location of injection: Arm left, Route of Administration: Intramuscular), administration date: 22Apr2021, when the patient was 45 years old, for COVID-19 immunization. The following information was reported: PYREXIA (non-serious) with onset 27Jan2022 06:00, outcome "recovering", described as "fever"; CHILLS (non-serious) with onset 27Jan2022 06:00, outcome "recovering", described as "Chills"; CHEST DISCOMFORT (non-serious) with onset 27Jan2022 06:00, outcome "recovering", described as "chest discomfort"; FATIGUE (non-serious) with onset 27Jan2022 06:00, outcome "recovering", described as "fatigue"; LYMPHADENOPATHY (non-serious) with onset 27Jan2022 06:00, outcome "recovering", described as "lymph node swelling". Therapeutic measures were not taken as a result of pyrexia, chills, chest discomfort, fatigue, lymphadenopathy.  Additional information: The patient did not receive any other medications in two weeks. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The device date was reported as 29Jan2022. The case was assessed as non-serious.  No follow-up attempts are possible. No further information is expected.
I started running a light fever and had some swelling on my lymph nodes, 48 hours later (03/10/2021) I noticed after taking a shower I had a rash on my breast on the side I got the vaccine. It was red and squashy. I waited a while to see if it went away. I took my second shot on the same arm. 2 days after my second shot 04/07/2021 I had a round circular looking like bruise on my right hip and left shoulder blade. Same shape and color and they are identical. I went to my OBGYN and she looked at my breast and she did an ultrasound and mammogram said everything was ok so she sent me to my primary doctor. She did some blood work, and everything was ok too. She sent me to a dermatologist.
I have a huge red spot and its about the size of my hand, my doctor is treating me with a steroid an if that does not work we will start a antibiotic, my arm is very swollen and hot to touch
This case was reported by a healthcare professional and described the occurrence of swelling injection site in a 29-year-old female subject who was vaccinated with FLULAVAL. On 14 October 2008 at 16:30, the subject received a dose of FLULAVAL (.5ml, unknown, right arm). At an unspecified time after vaccination with FLULAVAL, the subject experienced swelling injection site and injection site redness. At the time of reporting the outcome of the events were unspecified. Follow-up information was received on 24 November 2008, via healthcare professional. No new information was provided.
arm soreness; fatigue; back ache; upset stomach; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP and Pharmacist). The reporter is the patient.  A 41-year-old male patient received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 30Sep2023 as dose 1, single (Batch/Lot number: unknown) at the age of 41 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "recovering", described as "arm soreness"; FATIGUE (non-serious), outcome "recovering"; BACK PAIN (non-serious), outcome "recovering", described as "back ache"; ABDOMINAL DISCOMFORT (non-serious), outcome "recovering", described as "upset stomach". Therapeutic measures were not taken as a result of pain in extremity, fatigue, back pain, abdominal discomfort.  Additional Information: The patient have no other vaccine in four weeks. Unknown if patient had COVID prior vaccination and was not tested post vaccination.  The information on the batch/lot number for bnt162b2 omi xbb.1.5 has been requested and will be submitted if and when received.
shingles; pain; rash; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 75-year-old female patient who received Herpes zoster (Shingrix) (batch number 3P25J, expiry date 21st September 2021) for prophylaxis.   On 5th March 2019, the patient received the 1st dose of Shingrix. On an unknown date, 30 days after receiving Shingrix, the patient experienced shingles, pain and rash. On an unknown date, the outcome of the shingles was unknown and the outcome of the pain was recovering/resolving and the outcome of the rash was resolved with sequelae.   It was unknown if the reporter considered the shingles, pain and rash to be related to Shingrix.  Additional details were provided as follows: The reporter stated that, the patient developed shingles, rash and pain. The rash had resolved but the pain was ongoing
Patient received vaccine, was leaving pharmacy and fainted near front register.  Pt immediately said she was fine. I asked patient if she had eaten or drank anything today and she said yes. I asked them to sit back at the pharmacy but they left.
Patient came to pharmacy next day with Left arm red, inflamed and warm to the touch. parents were very concerned so he was referred to local after hours pediatric office.
6/27/2022 about noon I started to feel bad.  Lethargy, headache, and a cough developed overnight.  6/28 all symptoms got worse over the course of the day.  6/29 Symptoms got worse and I took home COVID 19 test, positive.  6/30 cough and fever improved.  7/1 Tested again and it was positive. 7/6 went to see doctor, who prescribed antibiotics to combat ear and bronchial infections. 7/7 symptoms improving but congestion lingers.
BREAKTHROUGH COVID INFECTION. TESTED POSITIVE ON 07/09/2021. PATIENT FULLY VACCINATED ON 02/03/2021.
A physician reported that a 33 year old female inadvertently, received an injection of Diphtheria and Tetanus Toxoids Adsorbed Ultrafined, Pediatric on 3/14/00 and experienced an injection site reaction characterized by swelling, redness and pain. The pt also developed a fever. On 3/16/00, she was treated with Augmentin and recovered on 3/23/00. Information received from the vaccine provider on 4/20/00 supplied pt data and stated that the pt recovered.
injection site bleeding; discomfort at injection site; Vaccination site pain; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE HAEMORRHAGE (injection site bleeding), VACCINATION SITE DISCOMFORT (discomfort at injection site) and VACCINATION SITE PAIN (Vaccination site pain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history was reported). Concomitant products included NIFEDIPINE and LOSARTAN for an unknown indication.   On 07-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Mar-2021, the patient experienced INJECTION SITE HAEMORRHAGE (injection site bleeding), VACCINATION SITE DISCOMFORT (discomfort at injection site) and VACCINATION SITE PAIN (Vaccination site pain). At the time of the report, INJECTION SITE HAEMORRHAGE (injection site bleeding), VACCINATION SITE DISCOMFORT (discomfort at injection site) and VACCINATION SITE PAIN (Vaccination site pain) outcome was unknown.            Treatment medication taken was paracetamol.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Severe body aches and fatigue, fever (101 degrees F). Fever happened 3x times during the day, treated with Tylenol.
Child received vaccines DTaP, varicella at approx 7pm at 8:30 presented in office with welts to body: swelling over face no hx of allergies.
"Janssen Covid 19 EUA"  Patient received her Janssen covid 19 today, she has had a history of fainting from vaccines in the past.  I administered her vaccine and moments after she reported she was feeling faint.  We laid her down on the floor and applied an ice pack to her neck.  She never lost consciousness.  I had her wait for 30 additional minutes and the patient was feeling better when she left.
Myalgia malaise Narrative:  missed work following second dose of vaccine  Other Relevant History:
arm pain and low-grade fever went away after 2-3 days, weakness and dizziness persist.
new onset of redness at the injection site.; swelling of the injection arm(right arm); soreness of the injection arm; headache; bad body ache / quoted," body pain felt like ran over by a car",/; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (swelling of the injection arm(right arm)), ARTHRALGIA (soreness of the injection arm), HEADACHE (headache), MYALGIA (bad body ache / quoted," body pain felt like ran over by a car",/) and INJECTION SITE ERYTHEMA (new onset of redness at the injection site.) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 048B21A and 049C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 01-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 05-Jun-2021, the patient experienced PERIPHERAL SWELLING (swelling of the injection arm(right arm)), ARTHRALGIA (soreness of the injection arm), HEADACHE (headache) and MYALGIA (bad body ache / quoted," body pain felt like ran over by a car",/). On 08-Jun-2021, the patient experienced INJECTION SITE ERYTHEMA (new onset of redness at the injection site.). At the time of the report, PERIPHERAL SWELLING (swelling of the injection arm(right arm)), ARTHRALGIA (soreness of the injection arm), HEADACHE (headache), MYALGIA (bad body ache / quoted," body pain felt like ran over by a car",/) and INJECTION SITE ERYTHEMA (new onset of redness at the injection site.) outcome was unknown.            Concomitant product was not provided by the reporter.  Treatment information was not provided  The patient received both scheduled doses of mRNA-1273 prior to the event; therefore, action taken with the drug in response to the event was not applicable
Elbows were swollen; Patient got like an allergic reaction, small red bumps, raised up and covered all hands, legs all over their body. It looks like the chicken pox with big bumps; This spontaneous case was reported by a pharmacist and describes the occurrence of HYPERSENSITIVITY (Patient got like an allergic reaction, small red bumps, raised up and covered all hands, legs all over their body. It looks like the chicken pox with big bumps) and JOINT SWELLING (Elbows were swollen) in an 83-year-old female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) (batch no. 8092) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Pfizer (Dose 1), Pfizer (Dose 3) and Pfizer (Dose 2). Past adverse reactions to the above products included No adverse reaction with Pfizer, Pfizer and Pfizer. Concomitant products included INFLUENZA VACCINE (FLU [INFLUENZA VACCINE]) from 12-Oct-2023 to an unknown date for an unknown indication.    On 12-Oct-2023, the patient received fourth dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) .5 milliliter. On 12-Oct-2023,  after starting mRNA-1273.815 (SPIKEVAX 2023-2024), the patient experienced HYPERSENSITIVITY (Patient got like an allergic reaction, small red bumps, raised up and covered all hands, legs all over their body. It looks like the chicken pox with big bumps). On an unknown date, the patient experienced JOINT SWELLING (Elbows were swollen). At the time of the report, HYPERSENSITIVITY (Patient got like an allergic reaction, small red bumps, raised up and covered all hands, legs all over their body. It looks like the chicken pox with big bumps) had not resolved and JOINT SWELLING (Elbows were swollen) outcome was unknown.        For mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown), the reporter did not provide any causality assessments.   By Saturday patient could not handle it and called the doctor. Patient got a steroid to get it calmed down and the patient was still getting the reaction. Reaction started the evening they received the vaccine. It started in the arm of the Moderna and then spread. The flu vaccine was given on a different arm.
Following vaccination, patient experienced chest pain, throat tightness, dizziness, nauseous, heart racing, initially hypertensive with elevated pulse. Transported the the emergency department.
This case was reported by a healthcare professional and described the occurrence of weakness in a 93-year-old female subject who was vaccinated with FLULAVAL (GlaxoSmithKline). Concurrent medical conditions included chronic obstructive pulmonary disease, elevated cholesterol, hypothyroidism, osteoporosis, pernicious anemia and restless legs syndrome. Concurrent medications included PREMARIN, SPIRIVA, SYNTHROID, Non-GSK Propanolol, Aspirin, XANAX, TANDEM Plus, PROTONIX, QUESTRAN, Vitamin D and B vitamins. On 21 September 2010 at 08:45 the subject received a dose of FLULAVAL (.5 ml, unknown, right arm). On an unspecified date, approximately 2 weeks after vaccination with FLULAVAL, the subject experienced episodic symptoms of weakness, hot flash and cardiac arrhythmia. The subject received unspecified treatment. At the time of reporting the events were unresolved. Follow-up information was received via the reporter on 08 December 2010. It was reported that the events began on 11 October 2010, 20 days following administration of FLULAVAL. The events were unresolved and reported to be unrelated to treatment with FLULAVAL.
This spontaneous report as received from a registered nurse refers to unspecified patients of unknown age and gender. The patients' concurrent conditions, medical history and concomitant medications were not reported. On unknown dates, the patients were vaccinated with improperly stored VARIVAX, lot # M035142, expiry date 13-AUG-2018, lot # M025867, expiry date 24-MAY-2018, lot # M033904, expiry date 20-JUL-2018, lot # L010148, expiry date 24-MAR-2017, lot # M017292, expiry date 07-APR-2018, lot # M023382, expiry date 11-MAY-2018, lot # L046887, expiry date 23-NOV-2017 (dose, route and site of administration were not reported) for prophylaxis. No adverse effects were reported. Administered vaccines underwent a temperature excursion of 5 to 14 degrees Fahrenheit for 2 hours and 5 to 14 degrees Fahrenheit for 5 hours 10 minutes. This is one of several cases received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1701USA007865: US-009507513-1701USA007866.
Patient was given 4th dose of monovalent vaccine instead of getting the bivalent booster.
Tonic clonic seizures within 48 hour vaccine administration. Taken to hospital ER. Admitted to PICU at hospital. Required antiepileptics to stop seizures.
My COVID-19 infection symptoms started on 12/26/2022 in morning. I had a sore throat. It was the worse sore throat I've ever had. I had a bad headaches and at night I had a moderate cough. I tested with a home COVID-19 test on the 12/27/2022 which was positive. I went to the clinic on 12/29/2022. They tested me back again for COVID-19 which was positive again. They ask me if I wanted to take the PAXLOVID but when the doctor saw my medication list, she told me not to take PAXLOVID because of the medication I was taking. They told me to take TYLENOL for fever and aches/ pains. I quarantined for 10 days. On 01/04/2023 I took another COVID-19 test which was negative. After testing negative due to COVID-19 infection I lost sense of taste/smell, low of energy and fatigued. My sense of taste hasn't come back to normal yet. I am not allowed to take any antihistamine because of increased heart rate. It took me 6-7 weeks to recover.
Immediately after injection, redness appeared and proceeded to get redder As the day wore on until it was down to the elbow by 3 pm and slightly raised . Redness lasted one week.
pain and soreness; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2), administration date 28Feb2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN (non-serious), outcome "unknown", described as "pain and soreness".  Additional Information: The patient reported that she had the vaccine shot on her left side and pain and soreness was on her right side.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
10 days after MMR developed red, papular plaque-like rash on trunk and upper extremities.  No itching.  No systemic symptoms. Rash gone 02/09/2004.
Client received a vaccine that expired on 07/27/2021. Client tolerated well and had no adverse reaction.
On 03-28-03, day 8 post vaccination, this non-naive vaccinee reported an oral ulcer on the inner aspect of the lower lip.  Vaccinee was afrebrile and no pain or tenderness was reported.  On day 11, vaccinee reported the ulcer resolved approximately 24 hours after onset.  Reports prior history of similar type of oral lesions.
No adverse event / No adverse effects; Improperly stored vaccine was administered; This spontaneous report was received from a nurse referring to a 14-year-old female patient. The patient's concurrent conditions, medical history and concomitant medications were not provided. Her historical vaccines included diphtheria vaccine toxoid (+) pertussis vaccine acellular (+) tetanus vaccine toxoid (DTAP VACCINE), influenza vaccine, Haemophilus influenzae type B (HIB) vaccine, hepatitis A vaccine (unknown manufacturer), hepatitis B vaccine (unknown manufacturer), injectible polio vaccine, meningococcal vaccine A/C/Y/W CONJ (DIP TOX) (MENACTRA), measles vaccine (+) mumps vaccine (+) rubella vaccine (unknown manufacturer), diphtheria vaccine toxoid (+) hepatitis b vaccine (+) RHBSAG (yeast) (+) pertussis vaccine acellular 3-component (+) polio vaccine inact 3v (vero) (+) tetanus vaccine toxoid (PEDIARIX), pneumococcal vaccine (unknown manufacturer) and varicella vaccine (unknown manufacturer).    On 20-JUN-2022, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, administered for prophylaxis (strength, dose, route of administration, anatomical location, lot # and expiry date were not provided). On 19-JUN-2023, the patient was vaccinated with the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, administered intramuscularly (IM) lot number W011455 and expiration date was reported as (11-DEC-2024)  for prophylaxis (strength and anatomical location were not provided) at a private Doctor's office/hospital.  The nurse reported that on 19-JUN-2023, hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) was administered with an improperly stored (product storage error). It was presented a temperature excursion with a temperature and time frame still unknown. It was reported that vaccine temperature excursion was not viable and occurred from a digital data logger alarm believed to be due to sensory issues. Monitoring temperature with back up logger. Temperature in range, new data logger was in use. It was also reported a storage in clinical practice.  This is one of several cases by the same reporter.
Headache, Myalgia, Arthralgia,  Fatigue  Narrative:  Felt like train it next morning, bad headache lasted a couple of days
Severe aching at injection site  Aching in all musculoskeletal joints Aching in gluteal muscles  Slight temperature  Fatigue
Pt presented to clinic with red raised area on left thigh, approx 18mm, which began 6-7 days after injection of vaccines. Rec'd HIB and Varicella injections in LT. Both nurse and mother believe it is the Varicella inj site. Pt has had 2 previous HIB inj, this was first Varicella. Also had episode of vomiting 2 days after shot lasted 2 days. No fever.
-No adverse event -Gave Monovalent for 3rd dose vs. bivalent
Fever; Body pain; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever) and MYALGIA (Body pain) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 08-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Feb-2021, the patient experienced PYREXIA (Fever) and MYALGIA (Body pain). At the time of the report, PYREXIA (Fever) and MYALGIA (Body pain) outcome was unknown. Not Provided    The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   It is reported that patient takes high blood pressure medication. Concomitant product use was not provided by the reporter.